nach oben

Erschienen in:

09.10.2015 | Original Article

MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2

verfasst von: Ruyi Zhang, Shujuan Yan, Jing Wang, Fang Deng, Yangliu Guo, Ya Li, Mengtian Fan, Qilin Song, Hongxia Liu, Yaguang Weng, Qiong Shi

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in young patients. However, treatment paradigms and survival rates have not improved in decades. MicroRNAs have been shown to be critical regulators of physiological homeostasis and pathological process, including bone disease. Nearly half of the microRNA (miRNA) genes are located at genomic regions and fragile sites known to be frequently deleted or amplified in various kinds of cancers. In this study, we investigated the role miR-30a in OS. A negative correlation between miR-30a expression and malignant grade was observed in OS cell lines. The overexpression of miR-30a reduced proliferation, migration, and invasion in 143B cells and the inhibitor of miR-30a increased proliferation, migration, and invasion in Saos2 cells. Further studies revealed that runt-related transcription factors 2 (Runx2) was a regulative target gene of miR-30a. Rescue assay significantly reversed the effects of overexpressing or inhibiting miR-30a. miR-30a also suppressed tumor formation and pulmonary metastasis in vivo. All the results suggest a critical role of miR-30a in suppressing proliferation, migration, and invasion of OS by targeting Runx2.

Barro V, Velez R, Pacha D, Giralt J, Roca I, Aguirre M. Bernese periacetabular osteotomy in a hip extra-articular resection followed by reconstruction using an extracorporeal irradiated acetabulum autograft with megaprosthesis, for proximal femur osteosarcoma in a pediatric patient. Case Rep Med. 2015;2015:813683. doi:10.1155/2015/813683.PubMedPubMedCentral

Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45(7):799–803. doi:10.1038/ng.2645.CrossRefPubMedPubMedCentral

Shao XJ, Miao MH, Xue J, Ji XQ, Zhu H. The down-regulation of microRNA-497 contributes to cell growth and cisplatin resistance through PI3K/Akt pathway in osteosarcoma. Cell Physiol Biochem. 2015;36(5):2051–62. doi:10.1159/000430172.CrossRefPubMed

Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet. 2003;145(1):1–30.CrossRefPubMed

Chen YU, Xu SF, Xu M, Yu XC. Postoperative infection and survival in osteosarcoma patients: reconsideration of immunotherapy for osteosarcoma. Mol Clin Oncol. 2015;3(3):495–500. doi:10.3892/mco.2015.528.PubMedPubMedCentral

Hattinger CM, Fanelli M, Tavanti E, Vella S, Ferrari S, Picci P, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 2015;1–20. doi:10.1517/14728214.2015.1051965.

Vimalraj S, Arumugam B, Miranda PJ, Selvamurugan N. Runx2: structure, function, and phosphorylation in osteoblast differentiation. Int J Biol Macromol. 2015;78:202–8. doi:10.1016/j.ijbiomac.2015.04.008.CrossRefPubMed

Guo YW, Chiu CY, Liu CL, Jap TS, Lin LY. Novel mutation of RUNX2 gene in a patient with cleidocranial dysplasia. Int J Clin Exp Pathol. 2015;8(1):1057–62.PubMedPubMedCentral

Wysokinski D, Pawlowska E, Blasiak J. RUNX2: a master bone growth regulator that may be involved in the DNA damage response. DNA Cell Biol. 2015;34(5):305–15. doi:10.1089/dna.2014.2688.CrossRefPubMed

10.

Bruderer M, Richards RG, Alini M, Stoddart MJ. Role and regulation of RUNX2 in osteogenesis. Eur Cell Mater. 2014;28:269–86.PubMed

11.

Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14(1):137. doi:10.1186/s12943-015-0404-3.CrossRefPubMedPubMedCentral

12.

Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, et al. ITGBL1 is a Runx2 transcriptional target and promotes breast cancer bone metastasis by activating the TGF-beta signaling pathway. Cancer Res. 2015. doi:10.1158/0008-5472.can-15-0240.

13.

Ge C, Zhao G, Li Y, Li H, Zhao X, Pannone G, et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene. 2015. doi:10.1038/onc.2015.91.PubMedCentral

14.

Nesbitt H, Browne G, O’Donovan KM, Byrne NM, Worthington J, McKeown SR, et al. Nitric oxide up-regulates RUNX2 in LNCaP prostate tumours: implications for tumour growth in vitro and in vivo. J Cell Physiol. 2015. doi:10.1002/jcp.25093.

15.

Li N, Luo D, Hu X, Luo W, Lei G, Wang Q, et al. RUNX2 and osteosarcoma. Anti Cancer Agents Med Chem. 2015;15(7):881–7.CrossRef

16.

Abdelzaher E, Kotb AF. High coexpression of runt-related transcription factor 2 (RUNX2) and p53 independently predicts early tumor recurrence in bladder urothelial carcinoma patients. Appl Immunohistochem Mol Morphol. 2015. doi:10.1097/pai.0000000000000193.

17.

Won KY, Park HR, Park YK. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori. 2009;95(3):311–6.PubMed

18.

van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA, et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem. 2012;287(7):4503–17. doi:10.1074/jbc.M111.287771.CrossRefPubMed

19.

Xue J, Niu YF, Huang J, Peng G, Wang LX, Yang YH, et al. miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3. Tumour Biol. 2014;35(12):12103–7. doi:10.1007/s13277-014-2513-9.CrossRefPubMed

20.

Sui C, Xu F, Shen W, Geng L, Xie F, Dai B, et al. Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET. Tumour Biol. 2015;36(3):1511–8. doi:10.1007/s13277-014-2679-1.CrossRefPubMed

21.

Huffaker TB, O’Connell RM. miR-155-SOCS1 as a functional axis: satisfying the burden of proof. Immunity. 2015;43(1):3–4. doi:10.1016/j.immuni.2015.06.020.CrossRefPubMed

22.

Belgardt BF, Ahmed K, Spranger M, Latreille M, Denzler R, Kondratiuk N, et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med. 2015;21(6):619–27. doi:10.1038/nm.3862.CrossRefPubMed

23.

Ma Y, She XG, Ming YZ, Wan QQ. miR-24 promotes the proliferation and invasion of HCC cells by targeting SOX7. Tumour Biol. 2014;35(11):10731–6. doi:10.1007/s13277-014-2018-6.CrossRefPubMed

24.

Nouraee N, Mowla SJ. miRNA therapeutics in cardiovascular diseases: promises and problems. Front Genet. 2015;6:232. doi:10.3389/fgene.2015.00232.

25.

Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 2015;5(10):1122–43. doi:10.7150/thno.11543.CrossRefPubMedPubMedCentral

26.

Wang F, Ren X, Zhang X. Role of microRNA-150 in solid tumors. Oncol Lett. 2015;10(1):11–6. doi:10.3892/ol.2015.3170.PubMedPubMedCentral

27.

Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010;29(29):4194–204.CrossRefPubMed

28.

Zhang X, Daucher M, Armistead D, Russell R, Kottilil S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS One. 2013;8(2):e55733. doi:10.1371/journal.pone.0055733.CrossRefPubMedPubMedCentral

29.

Ouzounova M, Vuong T, Ancey PB, Ferrand M, Durand G, Le-Calvez Kelm F, et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics. 2013;14:139. doi:10.1186/1471-2164-14-139.CrossRefPubMedPubMedCentral

30.

Wang T, Li F, Tang S. MiR-30a upregulates BCL2A1, IER3 and cyclin D2 expression by targeting FOXL2. Oncol Lett. 2015;9(2):967–71. doi:10.3892/ol.2014.2723.PubMed

31.

Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis. 2006;23(7-8):367–80. doi:10.1007/s10585-006-9046-6.CrossRefPubMed

32.

Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18(5):282–9.CrossRefPubMed

33.

Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–61.CrossRefPubMedPubMedCentral

34.

Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem. 2013;54:29–38. doi:10.1042/bse0540029.CrossRefPubMed

35.

Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014;33(19):2495–503. doi:10.1038/onc.2013.200.CrossRefPubMed

36.

Qi F, He T, Jia L, Song N, Guo L, Ma X, et al. The miR-30 family inhibits pulmonary vascular hyperpermeability in the premetastatic phase by direct targeting of Skp2. Clin Cancer Res. 2015;21(13):3071–80. doi:10.1158/1078-0432.ccr-14-2785.CrossRefPubMed

37.

Zhang Q, Tang Q, Qin D, Yu L, Huang R, Lv G, et al. Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis. Mol Cell Biol. 2015;35(6):988–1000. doi:10.1128/mcb.01242-14.CrossRefPubMedPubMedCentral

38.

Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Oncogene. 2013;32(33):3915–21. doi:10.1038/onc.2012.403.CrossRefPubMed

39.

Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182–6.CrossRefPubMed

40.

Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, et al. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov. 2015. doi:10.1158/2159-8290.cd-15-0125.PubMedPubMedCentral

41.

Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72(7):1865–77. doi:10.1158/0008-5472.can-11-2663.CrossRefPubMedPubMedCentral

42.

Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, et al. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol. 2004;166(1):85–95. doi:10.1083/jcb.200401138.CrossRefPubMedPubMedCentral

43.

He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (review). Oncol Lett. 2014;7(5):1352–62. doi:10.3892/ol.2014.1935.PubMedPubMedCentral

44.

Huang Q, Jiang Z, Meng T, Yin H, Wang J, Wan W, et al. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. Biochem Biophys Res Commun. 2014;453(1):160–5. doi:10.1016/j.bbrc.2014.09.076.CrossRefPubMed

45.

Wu T, Zhou H, Hong Y, Li J, Jiang X, Huang H. miR-30 family members negatively regulate osteoblast differentiation. J Biol Chem. 2012;287(10):7503–11. doi:10.1074/jbc.M111.292722.CrossRefPubMedPubMedCentral

Titel: MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2
verfasst von: Ruyi Zhang
Shujuan Yan
Jing Wang
Fang Deng
Yangliu Guo
Ya Li
Mengtian Fan
Qilin Song
Hongxia Liu
Yaguang Weng
Qiong Shi
Publikationsdatum: 09.10.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4086-7

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Alpha-linolenic acid regulates Cox2/VEGF/MAP kinase pathway and decreases the expression of HPV oncoproteins E6/E7 through restoration of p53 and Rb expression in human cervical cancer cell lines

Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?

Lin28: an emerging important oncogene connecting several aspects of cancer

The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma

MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway

Detection of Epstein-Barr virus genome and latent infection gene expression in normal epithelia, epithelial dysplasia, and squamous cell carcinoma of the oral cavity

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie